PRL and neoplasm: With dopamine agonist therapy, normalization of prolactin levels and tumor shrinkage occur in the vast majority of patients with prolactin-secreting microadenomas and macroadenomas, with shrinkage of macroprolactinomas in 92% of patients within six months and normalization of prolactin levels in 80-85% of patients within two years [6,7].